Top 10 Insider Purchases Last Month

6. Solid Biosciences Inc. (NASDAQ:SLDB)

Total value of insider purchases in February: $26,089,240.20

Market capitalization: $437.36 million

Solid Biosciences is a life sciences company based in Charleston, Massachusetts, focused on developing therapies for neuromuscular and cardiac diseases in the U.S. The company has several promising product candidates in its pipeline, including SGT-003, a gene transfer therapy for Duchenne muscular dystrophy, and SGT-501, designed to treat Catecholaminergic polymorphic ventricular tachycardia.

In February, Solid Biosciences announced promising initial data from the Phase 1/2 INSPIRE DUCHENNE trial of SGT-003. Interim 90-day biopsy results from the first three participants revealed an average microdystrophin expression of 110%, measured by western blot, along with improvements in several biomarkers indicative of muscle health and resilience.

Also in February, three insiders acquired a total of $26.09 million worth of Solid Biosciences shares at an average price of $5.21 per share. Year-to-date, the stock gained 40.38% and is now trading at $5.62 per share. Over the past 12 months, Solid Biosciences shares declined 50.75%.

Based on assessments from 12 analysts, Solid Biosciences stock has an average rating of “Strong Buy,” with a price target of $18.17, according to StockAnalysis. The average price target indicates an upside of 224.46% from the latest price.